echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > SKYRIZI (risankizumab-rzaa) and COSENTYX head-to-head study: SKYRIZI advantagesignificant

    SKYRIZI (risankizumab-rzaa) and COSENTYX head-to-head study: SKYRIZI advantagesignificant

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    AbbVie recently released the latest Phase IIIb head-to-head study data, which showed that the skin removal rate of psoriasis patients in the SKYRIZI group was better than that of the COSENTYX (secukinumab) group"We have seen the incredible positive impact of SKYRIZI (risankizumab-rzaa) on psoriasis patients," said DrRichard BWarren, lead researcher at AbbVieAt week 16, 74% of THE PATIENTS TREATED WITH SKYRIZI reached PASI 90, compared with 66% of patients treated with COSENTYXThe proportion of patients treated with SKYRIZI reaching PASI 90 at 52 weeks was 87% compared to 57% of patients treated with COSENTYX (p .001)At 52 weeks, 66% of patients with psoriasis treated with SKYRIZI had their skin completely removed - the psoriasis area reached a 100% removal rate (PASI 100), while only 40% of patients receiving COSENTYX reached PASI 100 (p 0.001)The data will be presented at the American Academy of Dermatology (AAD) virtual meeting in 2020
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.